|
1
|
Howlader N, Noone AM, Krapcho M, Miller D,
Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS,
Feuer EJ and Cronin KA: SEER Cancer Statistics Review, 1975–2018.
National Cancer Institute; Bethesda, MD: 2011
|
|
2
|
Hunger SP, Lu X, Devidas M, Camitta BM,
Gaynon PS, Winick NJ, Reaman GH and Carroll WL: Improved survival
for children and adolescents with acute lymphoblastic leukemia
between 1990 and 2005: A report from the children's oncology group.
J Clin Oncol. 30:1663–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pui CH, Carroll WL, Meshinchi S and Arceci
RJ: Biology, risk stratification, and therapy of pediatric acute
leukemias: An update. J Clin Oncol. 29:551–565. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eckert C, Parker C, Moorman AV, Irving JA,
Kirschner-Schwabe R, Groeneveld-Krentz S, Révész T, Hoogerbrugge P,
Hancock J, Sutton R, et al: Risk factors and outcomes in children
with high-risk B-cell precursor and T-cell relapsed acute
lymphoblastic leukaemia: Combined analysis of ALLR3 and ALL-REZ BFM
2002 clinical trials. Eur J Cancer. 151:175–189. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pui CH, Mullighan CG, Evans WE and Relling
MV: Pediatric acute lymphoblastic leukemia: Where are we going and
how do we get there? Blood. 120:1165–1174. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Woo JS, Alberti MO and Tirado CA:
Childhood B-acute lymphoblastic leukemia: A genetic update. Exp
Hematol Oncol. 3:162014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Esquela-Kerscher A and Slack FJ:
Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Montagner S, Dehó L and Monticelli S:
MicroRNAs in hematopoietic development. BMC Immunol. 15:142014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Carvalho de Oliveira J, Molinari Roberto
G, Baroni M, Bezerra Salomão K, Alejandra Pezuk J and Sol Brassesco
M: MiRNA dysregulation in childhood hematological cancer. Int J Mol
Sci. 19:26882018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gutierrez-Camino A, Garcia-Obregon S,
Lopez-Lopez E, Astigarraga I and Garcia-Orad A: MiRNA deregulation
in childhood acute lymphoblastic leukemia: A systematic review.
Epigenomics. 12:69–80. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Szczepanek J: Role of microRNA
dysregulation in childhood acute leukemias: Diagnostics, monitoring
and therapeutics: A comprehensive review. World J Clin Oncol.
11:348–369. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Durmaz B, Bagca BG, Cogulu O, Susluer SY,
Alpay A, Aksoylar S and Gunduz C: Antileukemic Effects of
Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and prednisolone on
childhood acute lymphoblastic leukemia. Biomed Res Int.
2021:32073282021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Stary J, Zimmermann M, Campbell M,
Castillo L, Dibar E, Donska S, Gonzalez A, Izraeli S, Janic D,
Jazbec J, et al: Intensive chemotherapy for childhood acute
lymphoblastic leukemia: Results of the randomized intercontinental
trial ALL IC-BFM 2002. J Clin Oncol. 32:174–184. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Licursi V, Conte F, Fiscon G and Paci P:
MIENTURNET: An interactive web tool for microRNA-target enrichment
and network-based analysis. BMC Bioinformatics. 20:5452019.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hsu SD, Lin FM, Wu WY, Liang C, Huang WC,
Chan WL, Tsai WT, Chen GZ, Lee CJ, Chiu CM, et al: miRTarBase: A
database curates experimentally validated microRNA-target
interactions. Nucleic Acids Res. 39:(Database issue). D163–D169.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gillespie M, Jassal B, Stephan R, Milacic
M, Rothfels K, Senff-Ribeiro A, Griss J, Sevilla C, Matthews L,
Gong C, et al: The reactome pathway knowledgebase 2022. Nucleic
Acids Res. 50((D1)): D687–D692. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Riehm H, Reiter A, Schrappe M, Berthold F,
Dopfer R, Gerein V, Ludwig R, Ritter J, Stollmann B and Henze G:
Corticosteroid-dependent reduction of leukocyte count in blood as a
prognostic factor in acute lymphoblastic leukemia in childhood
(therapy study ALL-BFM 83). Klin Padiatr. 199:151–160. 1987.(In
German). View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dördelmann M, Reiter A, Borkhardt A,
Ludwig WD, Götz N, Viehmann S, Gadner H, Riehm H and Schrappe M:
Prednisone response is the strongest predictor of treatment outcome
in infant acute lymphoblastic leukemia. Blood. 94:1209–1217. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Schrappe M, Möricke A, Reiter A, Henze G,
Welte K, Gadner H, Ludwig WD, Ritter J, Harbott J, Mann G, et al:
Key treatment questions in childhood acute lymphoblastic leukemia:
results in 5 consecutive trials performed by the ALL-BFM study
group from 1981 to 2000. Klin Padiatr. 225 (Suppl):S62–S72. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lauten M, Möricke A, Beier R, Zimmermann
M, Stanulla M, Meissner B, Odenwald E, Attarbaschi A, Niemeyer C,
Niggli F, et al: Prediction of outcome by early bone marrow
response in childhood acute lymphoblastic leukemia treated in the
ALL-BFM 95 trial: Differential effects in precursor B-cell and
T-cell leukemia. Haematologica. 97:1048–1056. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aye Y, Li M, Long MJ and Weiss RS:
Ribonucleotide reductase and cancer: Biological mechanisms and
targeted therapies. Oncogene. 34:2011–2021. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Su YF, Wu TF, Ko JL, Tsai HT, Tee YT,
Chien MH, Chou CH, Lin WL, Low HY, Chou MY, et al: The expression
of ribonucleotide reductase M2 in the carcinogenesis of uterine
cervix and its relationship with clinicopathological
characteristics and prognosis of cancer patients. PLoS One.
9:e916442014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thomas AL, Coarfa C, Qian J, Wilkerson JJ,
Rajapakshe K, Krett NL, Gunaratne PH and Rosen ST: Identification
of potential glucocorticoid receptor therapeutic targets in
multiple myeloma. Nucl Recept Signal. 13:e0062015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zuo Z, Zhou Z, Chang Y, Liu Y, Shen Y, Li
Q and Zhang L: Ribonucleotide reductase M2 (RRM2): Regulation,
function and targeting strategy in human cancer. Genes Dis.
11:218–233. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Han BW, Feng DD, Li ZG, Luo XQ, Zhang H,
Li XJ, Zhang XJ, Zheng LL, Zeng CW, Lin KY, et al: A set of miRNAs
that involve in the pathways of drug resistance and leukemic
stem-cell differentiation is associated with the risk of relapse
and glucocorticoid response in childhood ALL. Hum Mol Genet.
20:4903–4915. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yuan B, Zhang J, Wang H, Xiong L, Cai Q,
Wang T, Jacobsen S, Pradhan S and Wang Y: 6-Thioguanine reactivates
epigenetically silenced genes in acute lymphoblastic leukemia cells
by facilitating proteasome-mediated degradation of DNMT1. Cancer
Res. 71:1904–1911. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Selvakumar P, Lakshmikuttyamma A, Dimmock
JR and Sharma RK: Methionine aminopeptidase 2 and cancer. Biochim
Biophys Acta. 1765:148–154. 2006.PubMed/NCBI
|
|
29
|
Volk A, Liang K, Suraneni P, Li X, Zhao J,
Bulic M, Marshall S, Pulakanti K, Malinge S, Taub J, et al: A
CHAF1B-Dependent molecular switch in hematopoiesis and leukemia
pathogenesis. Cancer Cell. 34:707–723.e7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
El-Khazragy N, Elshimy AA, Hassan SS,
Matbouly S, Safwat G, Zannoun M and Riad RA: Dysregulation of
miR-125b predicts poor response to therapy in pediatric acute
lymphoblastic leukemia. J Cell Biochem. 120:7428–7438. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Piatopoulou D, Avgeris M, Marmarinos A,
Xagorari M, Baka M, Doganis D, Kossiva L, Scorilas A and Gourgiotis
D: MiR-125b predicts childhood acute lymphoblastic leukaemia poor
response to BFM chemotherapy treatment. Br J Cancer. 117:801–812.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schotte D, Chau JCK, Sylvester G, Liu G,
Chen C, van der Velden VH, Broekhuis MJ, Peters TC, Pieters R and
den Boer ML: Identification of new microRNA genes and aberrant
microRNA profiles in childhood acute lymphoblastic leukemia.
Leukemia. 23:313–322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chaudhuri AA, So AY, Mehta A, Minisandram
A, Sinha N, Jonsson VD, Rao DS, O'Connell RM and Baltimore D:
Oncomir miR-125b regulates hematopoiesis by targeting the gene
Lin28A. Proc Natl Acad Sci USA. 109:4233–4238. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Willimott S and Wagner SD: miR-125b and
miR-155 contribute to BCL2 repression and proliferation in response
to CD40 ligand (CD154) in human leukemic B-cells. J Biol Chem.
287:2608–2617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li XJ, Luo XQ, Han BW, Duan FT, Wei PP and
Chen YQ: MicroRNA-100/99a, deregulated in acute lymphoblastic
leukaemia, suppress proliferation and promote apoptosis by
regulating the FKBP51 and IGF1R/mTOR signalling pathways. Br J
Cancer. 109:2189–2198. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang L, Li X, Ke Z, Huang L, Liang Y, Wu
J, Zhang X, Chen Y, Zhang H and Luo X: MiR-99a may serve as a
potential oncogene in pediatric myeloid leukemia. Cancer Cell Int.
13:1102013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schotte D, De Menezes RX, Akbari Moqadam
F, Khankahdani LM, Lange-Turenhout E, Chen C, Pieters R and Den
Boer ML: MicroRNA characterize genetic diversity and drug
resistance in pediatric acute lymphoblastic leukemia.
Haematologica. 96:703–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Akbari Moqadam F, Lange-Turenhout EA,
Ariës IM, Pieters R and den Boer ML: MiR-125b, miR-100 and miR-99a
co-regulate vincristine resistance in childhood acute lymphoblastic
leukemia. Leuk Res. 37:1315–1321. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang H, Luo XQ, Zhang P, Huang LB, Zheng
YS, Wu J, Zhou H, Qu LH, Xu L and Chen YQ: MicroRNA patterns
associated with clinical prognostic parameters and CNS relapse
prediction in pediatric acute leukemia. PLoS One. 4:e78262009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Avigad S, Verly IR, Lebel A, Kordi O,
Shichrur K, Ohali A, Hameiri-Grossman M, Kaspers GJ, Cloos J,
Fronkova E, et al: miR expression profiling at diagnosis predicts
relapse in pediatric precursor B-cell acute lymphoblastic leukemia.
Genes Chromosomes Cancer. 55:328–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fang ZH, Wang SL, Zhao JT, Lin ZJ, Chen
LY, Su R, Xie ST, Carter BZ and Xu B: miR-150 exerts antileukemia
activity in vitro and in vivo through regulating genes in multiple
pathways. Cell Death Dis. 7:e23712016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Naderi T, Mohammadi-Yeganeh S,
Mohammadi-Hezaveh N, Hadavi R, Gharehbaghian A, Vazifeh-Shiran N,
Fallah Azad V and Paryan M: Investigating the inhibitory effect of
miR-34a, miR-449a, miR-1827, and miR-106b on target genes including
NOTCH1, c-Myc, and CCND1 in human T cell acute lymphoblastic
leukemia clinical samples and cell line. Iran J Basic Med Sci.
23:376–382. 2020.PubMed/NCBI
|
|
43
|
Verboon LJ, Obulkasim A, De Rooij JD,
Katsman-Kuipers JE, Sonneveld E, Baruchel A, Trka J, Reinhardt D,
Pieters R, Cloos J, et al: MicroRNA-106b ~ 25 cluster is
upregulated in relapsed MLL-rearranged pediatric acute myeloid
leukemia. Oncotarget. 7:48412–48422. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Xu L, Liang YN, Luo XQ, Liu XD and Guo HX:
Association of miRNAs expression profiles with prognosis and
relapse in childhood acute lymphoblastic leukemia. Zhonghua Xue Ye
Xue Za Zhi. 32:178–181. 2011.(In Chinese). PubMed/NCBI
|
|
45
|
Jiang L, Qian J, Yang Y and Fan Y:
Knockdown of MON1B exerts anti-tumor effects in colon cancer in
vitro. Med Sci Monit. 24:7710–7718. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kordes U, Krappmann D, Heissmeyer V,
Ludwig WD and Scheidereit C: Transcription factor NF-κB is
constitutively activated in acute lymphoblastic leukemia cells.
Leukemia. 14:399–402. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Ueno H, Yoshida K, Shiozawa Y, Nannya Y,
Iijima-Yamashita Y, Kiyokawa N, Shiraishi Y, Chiba K, Tanaka H,
Isobe T, et al: Landscape of driver mutations and their clinical
impacts in pediatric B-cell precursor acute lymphoblastic leukemia.
Blood Adv. 4:5165–5173. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Oh L, Hainaut P, Blanchet S and Ariffin H:
Expression of p53 N-terminal isoforms in B-cell precursor acute
lymphoblastic leukemia and its correlation with clinicopathological
profiles. BMC Cancer. 20:1102020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Nakagawa S, Kawahara K, Okamoto Y, Kodama
Y, Nishikawa T, Kawano Y and Furukawa T: Association between
dysfunction of the nucleolar stress response and multidrug
resistance in pediatric acute lymphoblastic leukemia. Cancers
(Basel). 14:51272022. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Devlin C, Greco S, Martelli F and Ivan M:
miR-210: More than a silent player in hypoxia. IUBMB Life.
63:94–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chan SY and Loscalzo J: MicroRNA-210: A
unique and pleiotropic hypoxamir. Cell Cycle. 9:1072–1083. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X,
Liu F, Wu M, Deng G, Ding W, et al: Effect of microRNA-210 on
prognosis and response to chemotherapeutic drugs in pediatric acute
lymphoblastic leukemia. Cancer Sci. 105:463–472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mei Y, Li Z, Zhang Y, Zhang W, Hu H, Zhang
P, Wu M and Huang D: Low miR-210 and CASP8AP2 expression is
associated with a poor outcome in pediatric acute lymphoblastic
leukemia. Oncol Lett. 14:8072–8077. 2017.PubMed/NCBI
|
|
54
|
Khalilian S, Hosseini Imani SZ and
Ghafouri-Fard S: Emerging roles and mechanisms of miR-206 in human
disorders: A comprehensive review. Cancer Cell Int. 22:4122022.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Sun H, Zhang Z, Luo W, Liu J, Lou Y and
Xia S: NET1 enhances proliferation and chemoresistance in acute
lymphoblastic leukemia cells. Oncol Res. 27:935–944. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Contreras Yametti GP, Ostrow TH, Jasinski
S, Raetz EA, Carroll WL and Evensen NA: Minimal residual disease in
acute lymphoblastic leukemia: Current practice and future
directions. Cancers (Basel). 13:18472021. View Article : Google Scholar : PubMed/NCBI
|
